{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-21-237729","form_type":"8-K","ticker":"PBYI","cik":"0001401667","company_name":"PUMA BIOTECHNOLOGY, INC.","filed_at":"2021-08-05T23:59:59+00:00","discovered_at":"2026-05-14T18:04:17.953866+00:00","generated_at":"2026-06-29T21:27:44.324106+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Puma Biotech Q2 2021 GAAP net loss $5.1M vs prior-year profit; NERLYNX flat at $48.9M","bullets":["GAAP net loss of $5.1M ($0.13 loss/share) vs net income of $3.4M in Q2 2020.","Non-GAAP adjusted net income $13.1M ($0.32/share) vs $14.0M ($0.36/share) in Q2 2020.","NERLYNX net revenue $48.9M, essentially flat vs $48.8M in Q2 2020.","Cash & securities $108.9M at June 30, 2021, up from $93.4M at Dec 31, 2020.","Received label expansion for NERLYNX dose escalation; SUMMIT top-line data expected Q4 2021."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-21-237729","json":"https://secwatch.observer/filing/0001193125-21-237729.json","markdown":"https://secwatch.observer/filing/0001193125-21-237729.md","text":"https://secwatch.observer/filing/0001193125-21-237729.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1401667/000119312521237729/0001193125-21-237729-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1401667/000119312521237729/d212533d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-29T21:27:44.324106+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}